The emerging use of bone marrow-derived mesenchymal stem cells in the treatment of human chronic wounds

Expert Opinion on Emerging Drugs

Volumn 18, Issue 4, 2013, Pages 405-419

  Dabiri, Ganary ^a   Heiner, Douglas ^a   Falanga, Vincent ^b  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow derived mesenchymal stem cell; Chronic wounds; Mesenchymal stem cell; Progenitor cells; Stem cells; Tissue regeneration; Tissue repair; Wound healing

Indexed keywords

ANTIINFECTIVE AGENT; CADEXOMER IODINE; PENTOXIFYLLINE; PLACEBO; PLATELET DERIVED GROWTH FACTOR BB; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RECOMBINANT EPIDERMAL GROWTH FACTOR;

BONE MARROW DERIVED MESENCHYMAL STEM CELL THERAPY; CHRONIC WOUND; COMPRESSION THERAPY; DEBRIDEMENT; DECUBITUS; DIABETIC FOOT; ELECTROSTIMULATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERBARIC OXYGEN; LEG AMPUTATION; LEG ULCER; LOW LEVEL LASER THERAPY; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PHOTOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCLEROTHERAPY; SKIN ULCER; TISSUE REGENERATION; ULTRASOUND THERAPY; VACUUM ASSISTED CLOSURE; VEIN SURGERY; WOUND CARE; WOUND HEALING;

BONE MARROW CELLS; CHRONIC DISEASE; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; WOUND HEALING; WOUNDS AND INJURIES;

EID: 84888865577     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2013.833184     Document Type: Review

References (117)

1. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999;34(10):738-46
2. Ilan N, Mahooti S, Madri JA. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J Cell Sci 1998;111(Pt 24):3621-31
3. Cha J, Falanga V. Stem cells in cutaneous wound healing. Clin Dermatol 2007;25(1):73-8
4. Nwomeh BC, Liang HX, Cohen IK, et al. MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers. J Surg Res 1999;81(2):189-95
5. Yager DR, Zhang LY, Liang HX, et al. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Invest Dermatol 1996;107(5):743-8
6. Hasan A, Murata H, Falabella A, et al. Dermal fibroblasts from venous ulcers are unresponsive to the action of transforming growth factor-beta 1. J Dermatol Sci 1997;16(1):59-66
7. Agren MS, Steenfos HH, Dabelsteen S, et al. Proliferation and mitogenic response to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age dependent. J Invest Dermatol 1999;112(4):463-9
8. Kim BC, Kim HT, Park SH, et al. Fibroblasts from chronic wounds show altered TGF-beta-signaling and decreased TGF-beta type II receptor expression. J Cell Physiol 2003;195(3):331-6
9. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005;366(9498):1736-43
10. Falanga V, Sabolinski M. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen 1999;7(4):201-7
11. Wu Y, Chen L, Scott PG, et al. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 2007;25(10):2648-59
12. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8(4):315-17
13. Amado LC, Saliaris AP, Schuleri KH, et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA 2005;102(32):11474-9
14. Li Y, Chen J, Zhang CL, et al. Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. Glia 2005;49(3):407-17
15. Jin HK, Carter JE, Huntley GW, et al. Intracerebral transplantation of mesenchymal stem cells into acid sphingomyelinase-deficient mice delays the onset of neurological abnormalities and extends their life span. J Clin Invest 2002;109(9):1183-91
16. Chen JS, Wong VW, Gurtner GC. Therapeutic potential of bone marrow-derived mesenchymal stem cells for cutaneous wound healing. Front Immunol 2012;3:192
17. Badiavas AR, Badiavas EV. Potential benefits of allogeneic bone marrow mesenchymal stem cells for wound healing. Expert Opin Biol Ther 2011;11(11):1447-54
18. Badiavas EV, Abedi M, Butmarc J, et al. Participation of bone marrow derived cells in cutaneous wound healing. J Cell Physiol 2003;196(2):245-50
19. Badiavas EV, Falanga V. Treatment of chronic wounds with bone marrow-derived cells. Arch Dermatol 2003;139:510-16
20. Wu Y, Zhao RC, Tredget EE. Concise review: bone marrow-derived stem/progenitor cells in cutaneous repair and regeneration. Stem Cells 2010;28(5):905-15
21. Wu Y, Wang J, Scott PG, et al. Bone marrow-derived stem cells in wound healing: a review. Wound Repair Regen 2007;15(Suppl 1):S18-26
22. Rustad KC, Wong VW, Sorkin M, et al. Enhancement of mesenchymal stem cell angiogenic capacity and stemness by a biomimetic hydrogel scaffold. Biomaterials 2012;33(1):80-90
23. Dash NR, Dash SN, Routray P, et al. Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. Rejuvenation Res 2009;12(5):359-66
24. Falanga V, Iwamoto S, Chartier M, et al. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng 2007;13(6):1299-312
25. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105(4):1815-22
26. Phillips T, Stanton B, Provan A, et al. A study of the impact of leg ulcers on quality of life: financial, social, and psychologic implications. J Am Acad Dermatol 1994;31(1):49-53
27. Schreml S, Szeimies RM, Prantl L, et al. Oxygen in acute and chronic wound healing. Br J Dermatol 2010;163(2):257-68
28. Panuncialman J, Falanga V. The science of wound bed preparation. Clin Plast Surg 2007;34(4):621-32
29. Falanga V. Classifications for wound bed preparation and stimulation of chronic wounds. Wound Repair Regen 2000;8(5):347-52
30. Falanga V. Care of venous leg ulcers. Ostomy Wound Manage 1999;45(1A Suppl):33S-43S
31. Fang RC, Galiano RD. A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Biologics 2008;2(1):1-12
32. FDA approved Drug products. Available from: http://www.accessdata.fda. gov/scripts/cder/drugsatfda/
33. Morimoto N, Yoshimura K, Niimi M, et al. An exploratory clinical trial for combination wound therapy with a novel medical matrix and fibroblast growth factor in patients with chronic skin ulcers: a study protocol. Am J Transl Res 2012;4(1);52-9
34. Hong JP, Jung HD, Kim YW. Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers. Ann Plast Surg 2006;56(4):394-8
35. Falanga V, Eaglstein WH, Bucalo B, et al. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 1992;18(7):604-6
36. Veves A, Falanga V, Armstrong DG, et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001;24(2):290-5
37. Eaglstein WH, Falanga V. Tissue engineering and the development of Apligraf a human skin equivalent. Adv Wound Care 1998;11(4 Suppl):1-8
38. Falanga V. Apligraf treatment of venous ulcers and other chronic wounds. J Dermatol 1998;25(12):812-17
39. Zaulyanov L, Kirsner RS. A review of a bi-layered living cell treatment (Apligraf-) in the treatment of venous leg ulcers and diabetic foot ulcers. Clin Interv Aging 2007;2(1):93-8
40. Tang JC, Marston WA, Kirsner RS. Wound Healing Society (WHS) venous ulcer treatment guidelines: what's new in five years? Wound Repair Regen 2012;20(5):619-37
41. Jankovic A, Binic I. Frequency rhythmic electrical modulation system in the treatment of chronic painful leg ulcers. Arch Dermatol Res 2008;300(7):377-83
42. Aziz Z, Cullum NA, Flemming K. Electromagnetic therapy for treating venous leg ulcers. Cochrnae Database Syst Rev 2013;2:CD002933
43. Fonder MA, Lazarus GS, Cowan DA, et al. Treating the chronic wound: a practical approach to the care of nonhealing wounds and wound care dressings. J Am Acad Dermatol 2008;58(2):185-206
44. Hunter JE, Teot L, Horch R, et al. Evidence-based medicine: vacuum-assisted closure in wound care management. Int Wound J 2007;4(3):256-69
45. Ubbink DT, Westerbos SJ, Evans D, et al. Topical negative pressure for treating chronic wounds. Cochrane Database Syst Rev 2008(3):CD001898
46. Thackham JA, McElwain DL, Long RJ. The use of hyperbaric oxygen therapy to treat chronic wounds: a review. Wound Repair Regen 2008;16(3):321-30
47. Falanga V, Lindholm C, Carson PA, et al. Text atlas of wound management. 2nd edition. Informa; New York, NY: 2012
48. Kranke P, Bennett MH, Martyn-St James M, et al. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev 2012;4:CD004123
49. Margolis DJ, Gupta J, Hoffstad O, et al. Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation: a cohort study. Diabetes Care 2013;36(7):1961-6
50. Reddy M. Pressure ulcers. Clin Evid (Online) 2011;2011
51. McInnes E, Bell-Syer SE, Dumville JC, et al. Support surfaces for pressure ulcer prevention. Cochrane Database Syst Rev 2008(4):CD001735
52. Darvall KA, Bate GR, Adam DJ, et al. Ultrasound-guided foam sclerotherapy for the treatment of chronic venous ulceration: a preliminary study. Eur J Vasc Endovasc Surg 2009;38(6):764-9
53. Pang KH, Bate GR, Darvall KA, et al. Healing and recurrence rates following ultrasound-guided foam sclerotherapy of superficial venous reflux in patients with chronic venous ulceration. Eur J Vasc Endovasc Surg 2010;40(6):790-5
54. Hertzman PA, Owens R. Rapid healing of chronic venous ulcers following ultrasound-guided foam sclerotherapy. Phlebology 2007;22(1):34-9
55. Falanga V, Fujitani RM, Diaz C, et al. Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized, placebo-controlled trial. Wound Repair Regen 1999;7(4):208-13
56. Jull AB, Arroll B, Parag V, et al. Pentoxifylline for treating venous leg ulcers. Cochrane Database Syst Rev 2012;12:CD001733
57. O'Meara S, Cullum N, Nelson EA, et al. Compression for venous leg ulcers. Cochrane Database Syst Rev 2012;11:CD000265
58. Sakata J, Sasaki S, Handa K, et al. A retrospective, longitudinal study to evaluate healing lower extremity wounds in patients with diabetes mellitus and ischemia using standard protocols of care and platelet-rich plasma gel in a Japanese wound care program. Ostomy Wound Manage 2012;58(4):36-49
59. Lacci KM, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med 2010;83(1):1-9
60. Tsay RC, Vo J, Burke A, et al. Differential growth factor retention by platelet-rich plasma composites. J Oral Maxillofac Surg 2005;63(4):521-8
61. Martinez-Zapata MJ, Marti-Carvajal AJ, Sola I, et al. Autologous platelet-rich plasma for treating chronic wounds. Cochrane Database Syst Rev 2012;10:CD006899
62. Jull AB, Walker N, Deshpande S. Honey as a topical treatment for wounds. Cochrane Database Syst Rev 2013;2:CD005083
63. Storm-Versloot MN, Vos CG, Ubbink DT, et al. Topical silver for preventing wound infection. Cochrane Database Syst Rev 2010(3):CD006478
64. Carter MJ, Tingley-Kelley K, Warriner RA III. Silver treatments and silver-impregnated dressings for the healing of leg wounds and ulcers: a systematic review and meta-analysis. J Am Acad Dermatol 2010;63(4):668-79
65. O'Meara S, Al-Kurdi D, Ologun Y, et al. Antibiotics and antiseptics for venous leg ulcers. Cochrane Database Syst Rev 2010(1):CD003557
66. Staylor A. Wound care devices: growth amid uncertainty. Med Tech Insights 2009;11(1):32-47
67. Broderick N. Understanding chronic wound healing. Nurs Practioner 2009;34(10):16-22
68. Collins N, Sloan C. Diabetic Wound Healing through Nurtition and Glycemic Control. 2013.7(3). Available from: www.todayswoundclinic.com
69. Stockl K, Vanderplas A, Tafesse E, et al. Costs of lower-extremity ulcers among patients with diabetes. Diabetes Care 2004;27(9):2129-34
70. Shahin ES, Dassen T, Halfens RJ. Pressure ulcer prevalence and incidence in intensive care patients: a literature review. Nurs Crit Care 2008;13(2):71-9
71. Gordon MD, Gottschlich MM, Helvig EI, et al. Review of evidenced-based practice for the prevention of pressure sores in burn patients. J Burn Care Rehabil 2004;25(5):388-410
72. Kuhn BA, Coulter SJ. Balancing the pressure ulcer cost and quality equation. Nurs Econ 1992;10(5):353-9
73. Gottrup F. A specialized wound-healing center concept: importance of a multidisciplinary department structure and surgical treatment facilities in the treatment of chronic wounds. Am J Surg 2004;187(5A):38S-43S
74. Gottrup F, Holstein P, Jorgensen B, et al. A new concept of a multidisciplinary wound healing center and a national expert function of wound healing. Arch Surg 2001;136(7):765-72
75. Worldwide Wound Management, Forecast to 2021: established and Emerging Products, Technologies and Markets in the Americas, Europe, Asia/Pacific and rest of the world. #S249. 2013. Available from: http://www. mediligence.com/rpt/ rpt-s249.htm
76. Phinney DG, Kopen G, Righter W, et al. Donor variation in the growth properties and osteogenic potential of human marrow stromal cells. J Cell Biochem 1999;75(3):424-36
77. Gregory CA, Prockop DJ, Spees JL. Non-hematopoietic bone marrow stem cells: molecular control of expansion and differentiation. Exp Cell Res 2005;306(2):330-5
78. Yoshikawa T, Mitsuno H, Nonaka I, et al. Wound therapy by marrow mesenchymal cell transplantation. Plast Reconstr Surg 2008;121(3):860-77
79. Fathke C, Wilson L, Hutter J, et al. Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair. Stem Cells 2004;22(5):812-22
80. Harris RG, Herzog EL, Bruscia EM, et al. Lack of a fusion requirement for development of bone marrow-derived epithelia. Science 2004;305(5680):90-3
81. Borue X, Lee S, Grove J, et al. Bone marrow-derived cells contribute to epithelial engraftment during wound healing. Am J Pathol 2004;165(5):1767-72
82. Li H, Fu X. Mechanisms of action of mesenchymal stem cells in cutaneous wound repair and regeneration. Cell Tissue Res 2012;348(3):371-7
83. Chen L, Tredget EE, Wu PY, et al. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE 2008;3(4):e1886
84. Kim WS, Park BS, Sung JH, et al. Wound healing effect of adipose-derived stem cells: a critical role of secretory factors on human dermal fibroblasts. J Dermatol Sci 2007;48(1):15-24
85. Wang CY, Yang HB, Hsu HS, et al. Mesenchymal stem cell-conditioned medium facilitates angiogenesis and fracture healing in diabetic rats. J Tissue Eng Regen Med 2012;6(7):559-69
86. Javazon EH, Keswani SG, Badillo AT, et al. Enhanced epithelial gap closure and increased angiogenesis in wounds of diabetic mice treated with adult murine bone marrow stromal progenitor cells. Wound Repair Regen 2007;15(3):350-9
87. Shome S, Rana T, Ganguly S, et al. Dopamine regulates angiogenesis in normal dermal wound tissues. PLoS ONE 2011;6(9):e25215
88. Shome S, Dasgupta PS, Basu S. Dopamine regulates mobilization of mesenchymal stem cells during wound angiogenesis. PLoS One 2012;7(2):e31682
89. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003;102(10):3837-44
90. Muehlberg FL, Song YH, Krohn A, et al. Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis 2009;30(4):589-97
91. Lin G, Yang R, Banie L, et al. Effects of transplantation of adipose tissue-derived stem cells on prostate tumor. Prostate 2010;70(10):1066-73
92. Zhang T, Lee YW, Rui YF, et al. Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. Stem Cell Res Ther 2013;4(3):70
93. Alvarez P, Carrillo E, Velez C, et al. Regulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing. Biomed Res Int 2013;2013:312656
94. Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res 2007;100(9):1249-60
95. Lee SH, Jin SY, Song JS, et al. Paracrine effects of adipose-derived stem cells on keratinocytes and dermal fibroblasts. Ann Dermatol 2012;24(2):136-43
96. Huang SP, Hsu CC, Chang SC, et al. Adipose-derived stem cells seeded on acellular dermal matrix grafts enhance wound healing in a murine model of a full-thickness defect. Ann Plast Surg 2012;69(6):656-62
97. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004;89(6):2583-9
98. Katz AJ, Llull R, Hedrick MH, et al. Emerging approaches to the tissue engineering of fat. Clin Plast Surg 1999;26(4):587-603
99. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 1976;4(5):267-74
100. Sundberg JP, Silva KA, McPhee C, et al. Skin diseases in laboratory mice: approaches to drug target identification and efficacy screening. Methods Mol Biol 2010;602:193-213
101. McFarlin K, Gao X, Liu YB, et al. Bone marrow-derived mesenchymal stromal cells accelerate wound healing in the rat. Wound Repair Regen 2006;14(4):471-8
102. Kwon DS, Gao X, Liu YB, et al. Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats. Int Wound J 2008;5(3):453-63
103. Sasaki M, Abe R, Fujita Y, et al. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol 2008;189:2581-7
104. Kirsner RS, Marston WA, Snyder RJ, et al. Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2012;380(9846):977-85
105. McCulloch EA, Till JE. The radiation sensitivity of normal mouse bone marrow cells, determined by quantitative marrow transplantation into irradiated mice. Radiat Res 1960;13:115-25
106. Thomson JA, Kalishman J, Golos TG, et al. Isolation of a primate embryonic stem cell line. Proc Natl Acad Sci USA 1995;92(17):7844-8
107. Rabbany SY, Pastore J, Yamamoto M, et al. Continuous delivery of stromal cell-derived factor-1 from alginate scaffolds accelerates wound healing. Cell Transplant 2010;19(4):399-408
108. Available from: http://www.clinicaltrials. gov/
109. Yufit T, Carson P, Falanga V. Topical delivery of cultured stem cells to human non-healing wounds: GMP facility development in an academic setting and FDA requirements for an IND for human testing. Curr Drug Deliv 2013; Epub ahead of print
110. Hoogduijn MJ, Dor FJ. Mesenchymal stem cells: are we ready for clinical application in transplantation and tissue regeneration? Front Immunol 2013;4:144
111. Wu Y, Huang S, Enhe J, et al. Insights into bone marrow-derived mesenchymal stem cells safety for cutaneous repair and regeneration. Int Wound J 2012;9:568-94
112. Ancans J. Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development. Front Immunol 2012;3:253
113. Unknown territory. Nature 2013;494(7435):5
114. Sipp D, Turner D. U.S. Regulation of stem cells as medical products. Science 2012;338:1296-7
115. Falanga V, Isaacs C, Paquette D, et al. Wounding of bioengineered skin: cellular and molecular aspects after injury. J Invest Dermatol 2002;119(3):653-60
116. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000;28(8):875-84
117. Kucia M, Reca R, Campbell FR, et al. A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia 2006;20(5):857-69